AVITA Medical, Inc. RCEL
17.65 USD +0.53 (+3.10%)
At closeNov 11, 2026, 4:14 AM EST
17.65 0.00 0.00%
Pre-market · Nov 11, 4:14 AM ET
16.52 Day range 17.82
3.22 52-week range 18.43
- YTD
- +411.59%
- 1 year
- +345.71%
News
seekingalpha.com AVITA Medical, Inc. (RCEL) Q3 2026 Earnings Call Transcript AVITA Medical, Inc. ( RCEL ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Ben Atkins - Vice President of Investor Relations & Corporate Communications Cary Vance -…
globenewswire.com AVITA Medical to Host Investor Webinar Briefing VALENCIA, Calif., Nov. 08, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering…
benzinga.com Lake Street Maintains Buy on AVITA Medical, Raises Price Target to $20 Lake Street analyst Frank Takkinen maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $12 to $20.
benzinga.com Texas Roadhouse To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Friday Wall Street analysts adjusted price targets and ratings for BlackLine, GXO Logistics, Karman, Helios, Wendy’s, Applied Optoelectronics and others.
marketbeat.com Avita Medical Q3 Earnings Call Highlights Avita Medical NASDAQ: RCEL raised its full-year revenue forecast for the second consecutive quarter after third-quarter sales rose 53% from a year earlier, driven by demand for its RECELL wound…
benzinga.com BTIG Maintains Buy on AVITA Medical, Raises Price Target to $21 BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $15 to $21.
benzinga.com AVITA Medical Q3 2026 Earnings Call Transcript AVITA Medical (NASDAQ:RCEL) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com AVITA Medical Q3 EPS $(0.20) Beats $(0.22) Estimate, Sales $25.862M Beat $22.200M Estimate AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.22) by 9.09 percent. This is a 56.52 percent increase over losses of…
benzinga.com AVITA Medical Raises FY2026 Sales Guidance from $86.000M-$89.000M to $92.000M-$94.000M vs $86.850M Est AVITA Medical (NASDAQ:RCEL) raises FY2026 sales outlook from $86.000 million-$89.000 million to $92.000 million-$94.000 million vs $86.850 million estimate.
globenewswire.com AVITA Medical Reports Third Quarter Results Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance VALENCIA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a…
globenewswire.com AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027 CMS finalizes nationally published physician valuations; CMS's four-code structure simplifies procedure reporting beginning January 1, 2027 VALENCIA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AVITA…
benzinga.com BTIG Maintains Buy on AVITA Medical, Raises Price Target to $15 BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $11 to $15.
benzinga.com AVITA Medical Q2 2026 Earnings Call Transcript On Thursday, AVITA Medical (NASDAQ:RCEL) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings…
benzinga.com TD Cowen Maintains Buy on AVITA Medical, Raises Price Target to $14 TD Cowen analyst Joshua Jennings maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $12 to $14.- benzinga.com BTIG Maintains Buy on AVITA Medical, Raises Price Target to $11 BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $7 to $11.
- benzinga.com AVITA Medical Announces PermeaDerm-I Study Met Primary Endpoint, Delivering Clinically Comparable Outcomes To Cadaveric Allograft With 70% Cost Reduction Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001) 96% reduction in preparation time and…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The market value of their outstanding shares is at $3.7 billion. As per the news, the Q1 earnings report…
benzinga.com This SpaceX Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday Wall Street analysts upgraded AVITA, Etsy, Unity, and raised target prices for these stocks. See what others think before buying Unity.- benzinga.com BTIG Upgrades AVITA Medical to Buy, Announces $7 Price Target BTIG analyst Ryan Zimmerman upgrades AVITA Medical (NASDAQ:RCEL) from Neutral to Buy and announces $7 price target.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market session. The market value of their outstanding shares is at $3.8 billion. The company's, Q1 earnings…- benzinga.com AVITA Medical Raises FY2026 Sales Guidance from $80.000M-$85.000M to $86.000M-$89.000M vs $82.350M Est AVITA Medical (NASDAQ:RCEL) raises FY2026 sales outlook from $80.000 million-$85.000 million to $86.000 million-$89.000 million vs $82.350 million estimate.
benzinga.com AVITA Medical Q2 EPS $(0.25) Beats $(0.29) Estimate, Sales $21.702M Beat $20.167M Estimate AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.29) by 13.79 percent. This is a 34.21 percent increase over losses of…
benzinga.com Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and revenue of $4.7 billion, leading to a 4.7% jump in pre-market trading. Other top gainers include…
benzinga.com Why ServiceNow Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket ServiceNow Inc (NOW) rose in pre-market trading after reporting better-than-expected Q2 results. LGCL, PLAG, EHGO, ZYBT, DOMO, AEHL, HYLN, LBGJ, RYAM gained. LESL, ZCMD, WHLR fell.- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's after-market session. The market value of their outstanding shares is at $143.1 million. Lisata Therapeutics…
- benzinga.com Lake Street Upgrades AVITA Medical to Buy, Raises Price Target to $6 Lake Street analyst Frank Takkinen upgrades AVITA Medical (NASDAQ:RCEL) from Hold to Buy and raises the price target from $3.5 to $6.
- benzinga.com AVITA Medical Reports Q1 2026 Results: Full Earnings Call Transcript
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com AVITA Medical Affirms FY2026 Sales Guidance of $80.000M-$85.000M vs $82.258M Est AVITA Medical (NASDAQ:RCEL) affirms FY2026 sales outlook from $80.000 million-$85.000 million to $80.000 million-$85.000 million vs $82.258 million estimate.
benzinga.com AVITA Medical Q1 EPS $(0.35) Misses $(0.28) Estimate, Sales $19.251M Beat $18.175M Estimate AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.28) by 25 percent. This is a 33.96 percent increase over losses of…
benzinga.com Earnings Scheduled For May 14, 2026 - benzinga.com AVITA Medical Appoints Cary Vance President, CEO; Jan Stern As Board Chair, Effective Immediately AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that its Board of Directors has appointed Cary Vance as President and Chief Executive…
- benzinga.com AVITA Medical Announces Data From Cohealyx-I Multi-Center Trial Shows Reduction Of ~20 Days In Mean Time To Skin Grafting For Participants With Full-Thickness Wounds AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced positive interim results from its Cohealyx-I multi-center study demonstrating a…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com AVITA Medical Enters Into 10-Yr Agreement With BARDA Valued At Up To $25.5M To Strengthen National Preparedness For Burn Mass Casualty Incidents Agreement ensures rapid nationwide access to RECELL® for burn mass casualty incidents, providing BARDA access to 3,000 units any time over the 10-year contract VALENCIA, Calif., April 08, 2026 (GLOBE…
- benzinga.com Northland Capital Markets Initiates Coverage On AVITA Medical with Outperform Rating, Announces Price Target of $10 Northland Capital Markets analyst Carl Byrnes initiates coverage on AVITA Medical (NASDAQ:RCEL) with a Outperform rating and announces Price Target of $10.
- benzinga.com D. Boral Capital Maintains Buy on AVITA Medical, Maintains $10 Price Target D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and maintains $10 price target.
- benzinga.com AVITA Medical Affirms FY2026 Sales Guidance of $80.000M-$85.000M vs $85.600M Est AVITA Medical (NASDAQ:RCEL) affirms FY2026 sales outlook from $80.000 million-$85.000 million to $80.000 million-$85.000 million vs $85.600 million estimate.
benzinga.com AVITA Medical Q4 Earnings Summary & Key Takeaways - benzinga.com AVITA Medical Q4 EPS $(0.38) Misses $(0.36) Estimate, Sales $17.616M Miss $17.838M Estimate AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 4.4 percent. This is a 13.64 percent increase over losses of…
- benzinga.com Earnings Scheduled For February 12, 2026
- benzinga.com D. Boral Capital Maintains Buy on AVITA Medical, Maintains $10 Price Target D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and maintains $10 price target.
- benzinga.com Lake Street Maintains Hold on AVITA Medical, Raises Price Target to $3.5 Lake Street analyst Frank Takkinen maintains AVITA Medical (NASDAQ:RCEL) with a Hold and raises the price target from $3 to $3.5.
- benzinga.com D. Boral Capital Maintains Buy on AVITA Medical, Lowers Price Target to $10 D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and lowers the price target from $14 to $10.
- benzinga.com AVITA Medical Reports FY25 Revenue Of $71.6M, Q4 Revenue Of $17.6M; Sees FY26 Revenue Of $80M-$85M AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced unaudited preliminary financial results and a…
benzinga.com This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday 
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com This Booz Allen Hamilton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday